Apellis Pharmaceuticals, Inc. (APLS): Price and Financial Metrics


Apellis Pharmaceuticals, Inc. (APLS): $34.00

0.08 (+0.24%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

APLS POWR Grades


  • Quality is the dimension where APLS ranks best; there it ranks ahead of 54.41% of US stocks.
  • APLS's strongest trending metric is Momentum; it's been moving down over the last 47 weeks.
  • APLS ranks lowest in Stability; there it ranks in the 11th percentile.

APLS Stock Summary

  • Apellis Pharmaceuticals Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 2.99% of US listed stocks.
  • Apellis Pharmaceuticals Inc's stock had its IPO on November 9, 2017, making it an older stock than merely 12.85% of US equities in our set.
  • APLS's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 96.53% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Apellis Pharmaceuticals Inc are PTCT, BLDP, FBIO, KDMN, and SLAB.
  • Visit APLS's SEC page to see the company's official filings. To visit the company's web site, go to www.apellis.com.

APLS Valuation Summary

  • APLS's price/earnings ratio is -12.4; this is 133.97% lower than that of the median Healthcare stock.
  • APLS's price/earnings ratio has moved up 13.1 over the prior 46 months.
  • APLS's EV/EBIT ratio has moved up 11 over the prior 46 months.

Below are key valuation metrics over time for APLS.

Stock Date P/S P/B P/E EV/EBIT
APLS 2021-08-31 22.8 -40.5 -12.4 -13.6
APLS 2021-08-30 22.6 -40.2 -12.4 -13.5
APLS 2021-08-27 23.0 -40.8 -12.5 -13.7
APLS 2021-08-26 22.2 -39.5 -12.1 -13.3
APLS 2021-08-25 21.3 -37.9 -11.6 -12.7
APLS 2021-08-24 21.2 -37.7 -11.6 -12.7

APLS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • APLS has a Quality Grade of C, ranking ahead of 54.41% of graded US stocks.
  • APLS's asset turnover comes in at 0.31 -- ranking 147th of 677 Pharmaceutical Products stocks.
  • AUPH, FENC, and ACST are the stocks whose asset turnover ratios are most correlated with APLS.

The table below shows APLS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.310 1 -0.607
2021-03-31 0.294 1 -0.434
2020-12-31 0.305 1 -0.496
2020-09-30 0.001 1 -1.018
2020-06-30 0.000 NA -1.210
2020-03-31 0.000 NA -2.534

APLS Price Target

For more insight on analysts targets of APLS, see our APLS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $67.81 Average Broker Recommendation 1.38 (Strong Buy)

APLS Stock Price Chart Interactive Chart >

Price chart for APLS

APLS Price/Volume Stats

Current price $34.00 52-week high $73.00
Prev. close $33.92 52-week low $27.50
Day low $32.86 Volume 1,222,011
Day high $34.44 Avg. volume 999,849
50-day MA $59.76 Dividend yield N/A
200-day MA $52.74 Market Cap 2.96B

Apellis Pharmaceuticals, Inc. (APLS) Company Bio


Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The company was founded in 2009 and is based in Crestwood, Kentucky.


APLS Latest News Stream


Event/Time News Detail
Loading, please wait...

APLS Latest Social Stream


Loading social stream, please wait...

View Full APLS Social Stream

Latest APLS News From Around the Web

Below are the latest news stories about Apellis Pharmaceuticals Inc that investors may wish to consider to help them evaluate APLS as an investment opportunity.

Apellis (APLS) Down on Mixed Data From Studies on GA Candidate

Apellis (APLS) posts mixed top-line data from the phase III DERBY and OAKS studies testing pegcetacoplan in adults with geographic atrophy secondary to age-related macular degeneration. Stock falls.

Yahoo | September 13, 2021

ISEE Stock: Why Rival Eye Drug Developer’s Disappointment Is a Boon to IVERIC bio

IVERIC bio (ISEE) stock is rocketing higher on Friday and there's a couple of catalysts behind the shares' positive movement today.

William White on InvestorPlace | September 10, 2021

APLS Stock: The Trial Results That Have Apellis Pharmaceuticals Plunging Today

Here's why investors are in full selloff mode today with APLS stock on Apellis Pharmaceuticals' latest clinical trial results.

Chris MacDonald on InvestorPlace | September 10, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

We're back at it again with one last day of trading this week and we're kicking it off with Friday's biggest pre-market stock movers.

William White on InvestorPlace | September 10, 2021

Apellis Loses A Third Of Its Value; Are Its Mixed Results Enough To Win FDA OK?

Apellis Pharmaceuticals reported mixed results for an eye-disease treatment, leading APLS stock to crash on Friday.

Yahoo | September 10, 2021

Read More 'APLS' Stories Here

APLS Price Returns

1-mo -41.29%
3-mo -43.44%
6-mo -22.64%
1-year 7.90%
3-year 82.99%
5-year N/A
YTD -40.56%
2020 86.81%
2019 132.15%
2018 -39.22%
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 3.1948 seconds.